This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

(Reuters) -The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, ...

What's driving a $20.52 billion market opportunity? The global soft tissue repair market, valued at US$15.12 billion in 2024, ...